Squarepoint Ops LLC acquired a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 29,001 shares of the company’s stock, valued at approximately $2,277,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. D. E. Shaw & Co. Inc. boosted its position in shares of Henry Schein by 3,387.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 251,756 shares of the company’s stock worth $19,768,000 after buying an additional 244,538 shares during the period. Bank of America Corp DE raised its holdings in shares of Henry Schein by 31.3% during the fourth quarter. Bank of America Corp DE now owns 676,661 shares of the company’s stock worth $53,131,000 after acquiring an additional 161,332 shares in the last quarter. Mackay Shields LLC raised its holdings in shares of Henry Schein by 28.1% during the fourth quarter. Mackay Shields LLC now owns 31,281 shares of the company’s stock worth $2,456,000 after acquiring an additional 6,861 shares in the last quarter. Achmea Investment Management B.V. raised its holdings in shares of Henry Schein by 98.0% during the fourth quarter. Achmea Investment Management B.V. now owns 32,236 shares of the company’s stock worth $2,530,000 after acquiring an additional 15,957 shares in the last quarter. Finally, Thoroughbred Financial Services LLC purchased a new stake in shares of Henry Schein during the fourth quarter worth $216,000.
Several analysts recently issued reports on HSIC shares. BidaskClub upgraded Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 27th. Zacks Investment Research upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Wednesday, January 30th. ValuEngine lowered Henry Schein from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Guggenheim started coverage on Henry Schein in a report on Wednesday. They set a “buy” rating and a $72.00 price objective for the company. Finally, Craig Hallum cut their price objective on Henry Schein from $96.00 to $72.00 and set a “buy” rating for the company in a report on Tuesday, February 19th. Seven analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $79.37.
NASDAQ HSIC traded up $0.77 during trading on Friday, hitting $61.50. 1,792,553 shares of the company traded hands, compared to its average volume of 1,422,073. Henry Schein, Inc. has a 12 month low of $56.58 and a 12 month high of $91.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.30 and a quick ratio of 0.68. The firm has a market cap of $9.19 billion, a P/E ratio of 14.89, a price-to-earnings-growth ratio of 2.29 and a beta of 0.88.
Henry Schein (NASDAQ:HSIC) last posted its earnings results on Wednesday, February 20th. The company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.01. The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.46 billion. Henry Schein had a return on equity of 19.86% and a net margin of 4.06%. The business’s revenue was up 1.7% compared to the same quarter last year. During the same period last year, the company earned $0.97 earnings per share. On average, equities analysts expect that Henry Schein, Inc. will post 3.43 EPS for the current year.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: Support Level
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.